The Gaucher and Pompe diseases enzyme replacement therapy (ERT) market is estimated to secure a valuation of US$ 3.3 billion in 2023 and is expected to rise to US$ 6.2 billion by 2033. The market is likely to capture a CAGR of 6.6% during the forecast period. The following factor driving the market is
High Cost of Treatment May Hinder Market Growth
Medicine and enzyme replacement therapy for Gaucher and Pompe disease may improve patients' conditions, although the market has a few restraining factors that may cause a decline in growth.
The increasing treatment cost of Pompe disease and its side effects may limit the market growth. The lack of skilled experts and medical workers and the adoption of alternative treatment options also decline the market growth.
While ERT has improved the prognosis in both infantile and later-onset Pompe and Gaucher diseases, the presence of the blood-brain barrier and pathological preconditions obstructs the effective uptake of ERT. As a result, efforts are being made to develop more precise treatment approaches. However, a shortage of skilled health professionals for this therapy and poor reimbursement regulations in emerging nations constrain market expansion.
Challenges Faced by Patients During COVID-19 Crisis Globally
Through distribution channels such as retail pharmacies, online pharmacies, hospital pharmacies, and speciality treatment pharmacies, the market is expanding around the globe. During the COVID-19 crisis, the healthcare sector was temporarily closed due to lockdowns, due to which patients suffering from chronic diseases faced several challenges with their regular medical checkups.
The distribution channels and suppliers stop their services due to social distancing. In the global market, the lack of medicine, doses, and shortage of beds and equipment decline the market size. The high-risk patients of lysosomal diseases due to direct involvement in respiratory, cardiac, and rental issues faced challenges. The operations, checkups, and appointments got postponed, and tragic deaths from the COVID-19 virus shook patients' minds due to fear.
| Attributes | Details |
|---|---|
| Market CAGR (2023 to 2033) | 6.6% |
| Market Valuation (2023) | US$ 3.3 billion |
| Market Valuation (2033) | US$ 6.2 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to Future Market Insights, the global Gaucher and Pompe diseases enzyme replacement therapy (ERT) market registered a healthy 6.6% CAGR during the forecast period. Historically, the market secured a CAGR of 7.4% between 2017 and 2022.
In enzyme replacement therapy, patients are administered various types of enzymes to overcome enzyme shortages/malfunctions. Increased prevalence of rare, chronic, and inherited diseases such as lysosomal storage diseases and genetic disorders is leading to the need for effective treatment options.
Infusions of an enzyme isolated from human or animal tissue or blood, or synthesized using innovative recombinant DNA techniques, replace the missing enzyme. A longer half-life of the drug, more potent action, resistance to degradation, or targeting a specific organ, tissue, or cell type are all possible modifications to an enzyme.
The body can complete the processes impeded by the deficiency by getting these enzyme replacements. Enzyme replacement therapies are designed to raise the concentration of enzymes, not to change the disease's underlying cause. ERT has been available for various lysosomal storage disorders, including several mucopolysaccharidoses (MPS).
The market is estimated to reach US$ 6.2 billion during the forecast period. Historically, the market stood at US$ 3.1 billion from 2017 to 2022.
| Segment | Therapeutic Condition |
|---|---|
| Top Category | Gaucher Disease |
| Historic CAGR | 7.8% |
| Forecast CAGR | 7.0% |
| Segment | Distribution Channel |
|---|---|
| Top Category | Specialty Treatment Pharmacies |
| Historic CAGR | 7.3% |
| Forecast CAGR | 6.6% |
Based on distribution channels, specialty treatment pharmacies are anticipated to dominate the global market share by securing a CAGR of 6.6% by 2033. The availability of treatment and patient preferences are growing in specialty treatment pharmacies may drive the market growth. Historically, specialty treatment pharmacies secured a CAGR of 7.3% between 2017 and 2022.
The growing popularity of retail and online pharmacies is due to the rising patients' demand for home-based ERT treatments. After the pandemic, online pharmacies rapidly grew, accounting for around 24.4% of the global market.
Hospital pharmacies are growing significantly by capturing a relevant CAGR in the global market by 2033. Emerging economies, advanced healthcare facilities, skilled professionals, and infusion therapy are advancing hospital pharmacies.
Principal Consultant
| Country | United States |
|---|---|
| Historic CAGR | 7.0% |
| Forecast CAGR | 6.1% |
| Valuation 2033 | US$ 1,329.3 million |
| Country | China |
|---|---|
| Historic CAGR | 8.0% |
| Forecast CAGR | 7.1% |
| Valuation 2033 | US$ 335.8 million |
| Country | Canada |
|---|---|
| Historic CAGR | 7.4% |
| Forecast CAGR | 6.9% |
| Valuation 2033 | US$ 159.5 million |
| Country | Germany |
|---|---|
| Historic CAGR | 7.0% |
| Forecast CAGR | 6.1% |
| Valuation 2033 | US$ 465.4 million |
| Country | United Kingdom |
|---|---|
| Historic CAGR | 7.8% |
| Forecast CAGR | 6.9% |
| Valuation 2033 | US$ 477.9 billion |
The United States is anticipated to dominate the global market by capturing a CAGR of 6.1% with a valuation of US$ 1,329.3 million by 2033. The rising urbanization, emerging economies, and developing healthcare infrastructure propel the United States Gaucher and Pompe diseases enzyme replacement therapy (ERT) market.
The growing technological advanced in healthcare equipment adoption of AI and IoT for diagnosis are fueling the market opportunities in the country. Healthcare providers research medicine by adopting the latest technologies. Increasing huge investment, urbanization, and new product launches are advancing the market size in the country. In the historical period, the United States secured a CAGR of 7.0% between 2017 and 2022.
China is anticipated to capture a CAGR of 7.1% with a valuation of US$ 335.8 million by 2033. The increasingly advanced healthcare infrastructure, medical facilities, and research and development activities fuel China's Gaucher and Pompe diseases enzyme replacement therapy (ERT) market. The country's innovation of enzyme replacement therapy is expanding its huge revenue.
The growing generic population, uncommon disorders, and Pompe disease treatment drive the market size. China captured a CAGR of 8.0% in the historical period between 2017 and 2022.
The United States is capturing a CAGR of 6.9% with a valuation of US$ 477.9 million during the forecast period. The increasing treatment modalities, hospital pharmacies, and therapy products fuel the market size. The strong presence of key players, increasing lysosomal disorder diseases, and Fabry disease fuel the market size.
The growing infusion facilities, healthcare infrastructure, government initiatives, and cutting-edge medical treatment drive the United Kingdom Gaucher and Pompe diseases enzyme replacement therapy (ERT) market. Healthcare manufacturers are developing budget-friendly therapy for low and middle-class patients to satisfy their requirements in the country. In the historical period, the United Kingdom captured a CAGR of 7.8% between 2017 and 2022.
Competitive Landscape
The essential players enact a significant role in the global market. Various healthcare providers and the pharmaceuticals sector focus on providing advanced equipment to satisfy patients' requirements. The prominent players invest a huge amount in research and development activities to acquire maximum output in the global market.
These players adopt marketing strategies, including partnerships, acquisitions, collaborations, product launches, agreements, and mergers. These players collect maximum revenue in the global market through distribution channels and suppliers. Launching innovative products and various therapeutic ailments are fueling the market size at another level.
A strong focus on acquiring regulatory approval further allows them to meet the increased need for treating lysosomal storage disorders across the globe.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ billion for Value |
| Key Countries Covered | United States, Canada, Germany, United Kingdom, France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Türkiye, Northern Africa, and South Africa |
| Key Segments Covered | Therapeutic Condition, Route of Administration, Distribution Channel, Region |
| Key Companies Profiled | Alexion Pharmaceuticals, Inc.; Pfizer; BioMarin Pharmaceuticals Inc; Ultragenyx Pharmaceutical Inc.; Janssen Pharmaceuticals, Inc (J&J); Sigma-Tau Pharmaceuticals Inc; AbbVie Inc.; Sanofi S.A.; Shire Plc; Merck KGaA; Takeda Pharmaceuticals |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
China, India, and Japan dominate the Asian market.
The market is valued at US$ 3.3 billion in 2023.
Sanofi, Genzyme Corporation, and Shire are key market players.
Japan, China, and India dominate the Asian market.
The market is estimated to reach US$ 6.2 billion by 2033.
North America is projected to emerge as a lucrative market.
1. Executive Summary | Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Disease, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease, 2023 to 2033 5.3.1. Gaucher Disease 5.3.1.1. Type 1 (Non-neuropathic) 5.3.1.2. Type 2 (Acute Infantile Neuronopathic) 5.3.1.3. Type 3 Gaucher Disease (Chronic Neuronopathic) 5.3.1.4. Perinatal Lethal Gaucher Disease 5.3.1.5. Cardiovascular Gaucher Disease 5.3.2. Pompe Disease 5.3.2.1. Classic Infantile-onset 5.3.2.2. Non-classic Infantile-onset 5.3.2.3. Late-onset 5.4. Y-o-Y Growth Trend Analysis By Disease, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Disease, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Oral 6.3.2. Parenteral 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Specialty Treatment Pharmacies 7.3.3. Retail Pharmacies 7.3.4. Online Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Disease 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Disease 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Disease 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Disease 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Disease 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Disease 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Disease 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Disease 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Disease 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Disease 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Disease 14.2.3. By Route of Administration 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Disease 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Disease 15.2.3. By Route of Administration 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Disease 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Disease 16.1.2.2. By Route of Administration 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Disease 16.2.2.2. By Route of Administration 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Disease 16.3.2.2. By Route of Administration 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Disease 16.4.2.2. By Route of Administration 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Disease 16.5.2.2. By Route of Administration 16.5.2.3. By Distribution Channel 16.6. United kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Disease 16.6.2.2. By Route of Administration 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Disease 16.7.2.2. By Route of Administration 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Disease 16.8.2.2. By Route of Administration 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Disease 16.9.2.2. By Route of Administration 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Disease 16.10.2.2. By Route of Administration 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Disease 16.11.2.2. By Route of Administration 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Disease 16.12.2.2. By Route of Administration 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Disease 16.13.2.2. By Route of Administration 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Disease 16.14.2.2. By Route of Administration 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Disease 16.15.2.2. By Route of Administration 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Disease 16.16.2.2. By Route of Administration 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Disease 16.17.2.2. By Route of Administration 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Disease 16.18.2.2. By Route of Administration 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Disease 16.19.2.2. By Route of Administration 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Disease 16.20.2.2. By Route of Administration 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Disease 16.21.2.2. By Route of Administration 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Disease 17.3.3. By Route of Administration 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Pfizer 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Alexion Pharmaceuticals, Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. BioMarin Pharmaceutical Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Ultragenyx Pharmaceutical Inc. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Janssen Pharmaceuticals, Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Sigma-Tau Pharmaceuticals Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. AbbVie Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Sanofi S.A. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Shire Plc 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Merck KGaA 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. Takeda Pharmaceuticals 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market
